Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Persistent Corneal Epithelial Defect: early-phase trial registry
2 of 2 indexed Persistent Corneal Epithelial Defect trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Persistent Corneal Epithelial Defect: 2 US clinical trials tracked, 2 recruiting.
Persistent Corneal Epithelial Defect is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Glaukos Corporation, running 1 of these trials.
Enrollment posture brief
Registry condition persistent-corneal-epithelial-defect
OPEN 2 | RECR 100% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Persistent Corneal Epithelial Defect lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Persistent Corneal Epithelial Defect on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Persistent Corneal Epithelial Defect is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED
Glaukos Corporation
NCT05966493
Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
University of Illinois at Chicago
NCT06919081
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Persistent Corneal Epithelial Defect records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Persistent Corneal Epithelial Defect trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Persistent Corneal Epithelial Defect page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Persistent Corneal Epithelial Defect trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Glaukos Corporation sponsors the most Persistent Corneal Epithelial Defect trials on record, review their full trial history before evaluating a specific study. See Glaukos Corporation's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Persistent Corneal Epithelial Defect condition card totals 2 registered trials; most-linked intervention lufepirsen low dose; top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.